Does EBO2 (EBOO) Work? An Honest Read of the Evidence

EBO2 (also called EBOO), described more fully in the pillar guide on what EBO2 is, is marketed with confident language about detoxification and cellular health, so it is worth asking plainly whether it works. The honest answer starts with what “work” would even mean here, moves through every study that has been published on EBOO specifically, and ends with why personal testimonials are not a substitute for that research.

What “work” would mean

A treatment “working” implies a measurable endpoint (a symptom score, a lab value, a rate of complications) compared against something: a placebo, standard care, or no treatment. Without a comparator, a report that patients improved cannot separate the treatment’s own effect from everything else that happens to a person between one appointment and the next. For EBOO specifically, almost none of the published record includes that kind of comparison. Most of it describes what happened to a small number of patients who received the treatment, without a comparison group that did not, which is a meaningfully weaker kind of evidence than a randomized trial even before looking at how few patients are involved.

Every EBOO study, one paragraph each

The earliest human report on the technique describes its own inventors self-testing the device, noting the disappearance of lipomas after six treatments, then using it in a patient with Madelung disease and an unspecified number of patients with atherosclerotic vasculopathy. It reports perceived clinical benefit and no observed side effects, but it is an uncontrolled case series performed by the device’s own inventors, including self-experimentation, with no blinding, randomization, or precisely reported total sample size [1].

A single case report from the same research group describes one dialysis patient with necrotizing fasciitis, a serious soft-tissue infection, who improved after EBOO was added when standard therapy had not worked. The authors describe EBOO as already used routinely at their hospital, but this is one patient with no control, randomization, or blinding, and no reported long-term follow-up [2].

A narrative review by the technique’s developers describes the EBOO method itself, a continuous circuit combining filtration with oxygen and ozone exchange, and argues that it delivers a more controlled ozone dose to a larger blood volume than major autohemotherapy. It presents rationale and early observations rather than new controlled outcome data, and it contributes no additional patients to the total evidence base [3].

The one randomized controlled trial specific to EBOO assigned 28 patients with peripheral artery disease to either EBOO or intravenous prostacyclin. It found significantly greater regression of ischemic skin lesions and improved pain and well-being with EBOO, with no significant difference in measured arterial circulation between groups. The sample is small, drawn from a single Italian center, and the available report does not describe blinding of outcome assessors or the randomization method [4].

A bench study from the same research group tested a redesigned gas exchange device using a buffered saline solution, not blood, and measured how efficiently oxygen and ozone moved into that solution, reporting minimal foreign surface contact along the way. That result speaks to the device’s engineering and says nothing about any clinical benefit, since the study involved no blood, no patients, and no clinical outcome of any kind [5].

The most recent addition to the literature, from 2025, is a single case report describing an 88-year-old woman with chronic anemia whose urinary toxin-to-creatinine ratios declined after two series of EBOO treatments, with one measured heavy metal, nickel, not declining and hemoglobin remaining largely unchanged. It is a case report by clinicians not connected to the technique’s developers, describing their own patient’s course rather than a study designed and run by the inventing team, though it remains a single patient with no control for ongoing environmental exposure between measurements, and the authors themselves state that it cannot establish causation or generalize beyond that one patient [6].

Counting only the studies above that report a specific number of human participants, the 28-patient trial and the two single-patient case reports, the total is 30 people across every controlled or case-based study of EBOO ever published. The 2000 case series adds an unknown small number more, and the bench test and the review contribute no patients at all. No independent research group has replicated any of these findings. Five of the six studies share overlapping authorship from the team that invented the technique; the sixth is a single 2025 case report that, on its own, does not confirm or refute anything the earlier reports found.

What ozone therapy generally has shown, and why it does not transfer

Ozone delivered by other routes has a larger, though still mixed, evidence base. A Cochrane review pooling three small randomized trials of ozone for diabetic foot ulcers, 212 participants total, found one trial with better outcomes for ozone over antibiotics but no significant difference from usual care when the other two were pooled, and the review authors say they cannot draw firm conclusions [8]. A more recent meta-analysis pooling 424 patients from randomized trials found intra-articular ozone injections produced pain scores statistically similar to hyaluronic acid injections in knee osteoarthritis at four to six months, with no placebo-controlled comparison included [9]. Proponents of ozone therapy argue that a brief, controlled ozone exposure triggers a beneficial oxidative stress response in blood cells, a mechanism described at length in the mechanistic literature [7]. Whatever the merits of that argument for a local injection into a joint, or a small autohemotherapy sample, it does not automatically apply to EBO2’s continuous, filtered, larger-volume circuit. The dose, route, and blood volume are different enough that evidence for one does not transfer cleanly to the other, which is exactly why the EBOO-specific record above, not the general ozone literature, is what should inform a decision about EBO2 itself. A companion guide compares EBO2 with the related autohemotherapy and 10-pass techniques in more detail.

Why people report feeling better

None of this means people are lying when they say they felt better after EBO2. Feeling better after any intervention is common and expected for reasons that have nothing to do with whether the intervention has a specific effect: a placebo response to an elaborate, expensive, hour-long procedure; the natural tendency for symptoms to improve over time regardless of treatment, sometimes called regression to the mean; other changes made around the same time, such as new supplements, diet changes, or more attention to sleep; and selection in what gets reported, since people who feel unchanged or worse are less likely to write a testimonial than people who feel better. The National Institutes of Health’s complementary health center puts this plainly: evidence from research studies is more reliable than something seen in an advertisement or heard from someone it worked for, and claims of a sudden breakthrough should be weighed against the fact that genuine research usually advances in small, incremental steps [10].

What would change the picture

A larger, independently conducted, randomized trial of EBO2 specifically, with a real comparator such as a sham procedure and a prespecified clinical endpoint, would change the picture considerably. So would independent replication of the 2025 toxin case report in more than one patient, ideally by a research group with no connection to the clinics selling the treatment. A registry that tracked outcomes across many EBO2 clinics over time, even without a formal control group, would be a meaningful step up from six scattered case reports and one small trial. Right now, none of that exists. Until it does, the honest description of the evidence is that it is thin, small, and mostly self-authored by the people who developed the technique, not that it has been disproven or that it definitely does nothing.

How to weigh clinic testimonials

Clinics offering EBO2 often publish patient testimonials describing more energy, less joint pain, or improved mental clarity. One clinic’s page quotes a patient describing joint pain that “decreased” and overall health that “improved significantly” after a few sessions, alongside a note that claims about heavy metals, microplastics, and parasites in the filtrate are still being investigated rather than established [11]. Another clinic’s page shares a patient’s account of a large volume of material described as inflammatory product appearing in the filter during one session compared with a much smaller amount at a previous visit [12]. These are real accounts of what patients noticed, and they are not evidence in the sense a clinical trial produces evidence: there is no comparison group, no blinding, and no attempt to rule out the explanations described above. A testimonial can be true and still not tell you what would have happened without treatment. Ozone therapy is not FDA-approved for any condition, and a testimonial does not change that regulatory status [13].

Bottom line

Does EBO2 work? The published, EBOO-specific record is one small randomized trial, two single-patient case reports, one case series with no reported total, one in vitro bench test, and one narrative review, adding up to about 30 documented patients with no independent replication [1][2][3][4][5][6]. That is not enough to say the treatment works for any condition, and it is not enough to say it does not, either; it means the question has not been seriously tested at the scale that would let anyone answer it with confidence. Anyone deciding whether to pay for a session should weigh that thin evidence base honestly against clinic testimonials and marketing language, ask what specifically a clinic can point to beyond the studies summarized here, ideally with a physician who can discuss it directly, and can review clinics offering the procedure with that context in mind rather than with the impression that a large body of research stands behind it.